Studien der Onkologischen Tagesklinik

KEYNOTE 937

adjuvant
Pembrolizumab (MK-3475) versus Placebo als adjuvante Therapie bei Patienten mit HCC und radiologischer Komplettremission nach chirurgischer Resektion oder lokaler Ablation

AIO-HEP 0418 DEMAND
Firstline
A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on 24-months survival rate in the treatment of unresectable hepatocellular carcinoma patients

IMMUWIN

Firstline
A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design

REACH-II
Secondline

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy other than Sorafenib

AURORA
Secondline
A Phase II, non-randomized, single arm, translational study of CAbozantinib for Patients with HepatocellUlaR CarcinOma (HCC) Refractory to LenvAtinib Treatment

CaboRise

Secondline
A phase II study evaluating reduced starting dose and dose escalation of Cabozantinib as second-line therapy for advanced HCC in patients with compensated liver cirrhosis

PROOF

Firstline

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations

AIO-HEP-0116 NALIRICC
Secondline

A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine and paltinum-based therapies

INNOVATION
Neoadjuvant - adjuvant
INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer

MOONLIGHT
Firstline
Modifiziertes FOLFOX mit Nivolumab und Ipilimumab bei Patienten mit unbe-handeltem, lokal fortgeschrittenen oder metastasierten Adenokarzinom des Magens oder des gastroösophagealen Übergangs. Eine randomisierte Phase 2 Studie

AIO-PAK-0114 ALPACA
Firstline
Induction treatment with nab-paclitaxel/gemcitabine for first-line treatment of metastatic pancreatic cancer followed by either alternating application of gemcitabine monotherapy and nab-paclitaxel/gemcitabine or continuing application of nab-paclitaxel/gemcitabine: A randomized phase II study

FOOTPATH
Firstline
A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer

LAPIS
Firstline
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neo-adjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer